Published in Cancer Epidemiol Biomarkers Prev on March 01, 2009
Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics (2012) 1.10
Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California. Cancer Epidemiol Biomarkers Prev (2011) 1.08
Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3. Cancer Epidemiol Biomarkers Prev (2010) 1.05
Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand. BMC Infect Dis (2013) 0.97
Clinical and pathological heterogeneity of cervical intraepithelial neoplasia grade 3. PLoS One (2012) 0.93
Heterogeneity of high-grade cervical intraepithelial neoplasia related to HPV16: implications for natural history and management. Int J Cancer (2012) 0.93
Type-specific prevalence of high-risk human papillomavirus by cervical cytology and age: Data from the health check-ups of 7,014 Korean women. Obstet Gynecol Sci (2013) 0.90
Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females. ISRN Obstet Gynecol (2011) 0.89
Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer. Cancer Epidemiol Biomarkers Prev (2014) 0.85
Age-group differences in human papillomavirus types and cofactors for cervical intraepithelial neoplasia 3 among women referred to colposcopy. Cancer Epidemiol Biomarkers Prev (2011) 0.85
No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study. J Infect Dis (2013) 0.83
HPV-based Tests for Cervical Cancer Screening and Management of Cervical Disease. Curr Obstet Gynecol Rep (2013) 0.82
Obesity Among Young Adults in Developing Countries: A Systematic Overview. Curr Obes Rep (2016) 0.81
Human papillomavirus prevalence in a population of women living in Port-au-Prince and Leogane, Haiti. PLoS One (2013) 0.80
Risk of Delayed Human Papillomavirus Vaccination in Inner-City Adolescent Women. J Infect Dis (2016) 0.78
Performance of self-collected cervical samples in screening for future precancer using human papillomavirus DNA testing. J Natl Cancer Inst (2014) 0.78
Prevalence of Human Papillomavirus Genotypes Among Women With High-Grade Cervical Lesions in Beijing, China. Medicine (Baltimore) (2016) 0.77
Inhibitors of differentiation-1 promotes nitrosopyrrolidine-induced transformation of HPV 16-immortalized cervical epithelial cell. Cancer Sci (2014) 0.75
Pre-vaccination type-specific HPV prevalence in confirmed cervical high grade lesions in the Māori and non-Māori populations in New Zealand. BMC Infect Dis (2015) 0.75
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39
Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer (2007) 10.29
Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst (2003) 6.28
The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst (2005) 6.03
Carcinogenicity of human papillomaviruses. Lancet Oncol (2005) 5.84
Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis (2005) 3.84
Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine (2006) 3.72
Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev Panam Salud Publica (1997) 3.67
Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst (2008) 3.32
Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine (2008) 3.17
Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst (2003) 2.81
Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis (2005) 2.51
Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst (2005) 2.47
Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res (2006) 2.33
Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica,. Rev Panam Salud Publica (2004) 2.33
The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res (2006) 2.08
Interobserver agreement in the assessment of components of colposcopic grading. Obstet Gynecol (2008) 1.96
Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res (2008) 1.83
Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer (2006) 1.43
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Replicating genotype-phenotype associations. Nature (2007) 16.11
Human papillomavirus and cervical cancer. Lancet (2007) 12.47
Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med (2002) 10.80
Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet (2010) 9.07
Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst (2013) 8.75
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology (2010) 7.24
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst (2005) 6.03
A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet (2009) 5.62
Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol (2011) 5.59
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol (2013) 5.40
Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst (2005) 5.29
The Diesel Exhaust in Miners study: a nested case-control study of lung cancer and diesel exhaust. J Natl Cancer Inst (2012) 5.27
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet (2011) 5.21
NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet (2005) 5.01
Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet (2002) 5.00
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol (2015) 4.84
The carcinogenicity of human papillomavirus types reflects viral evolution. Virology (2005) 4.72
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA (2007) 4.66
Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst (2011) 4.59
Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst (2007) 4.55
Powerful multilocus tests of genetic association in the presence of gene-gene and gene-environment interactions. Am J Hum Genet (2006) 4.40
Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine (2008) 4.31
Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst (2006) 4.14
Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol (2006) 4.13
MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci U S A (2008) 4.06
Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet (2002) 3.96
Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst (2010) 3.95
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst (2011) 3.92
Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One (2008) 3.87
Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis (2005) 3.84
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet (2009) 3.76
Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst (2008) 3.73
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol (2004) 3.67
A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis (2007) 3.59
Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol (2002) 3.53
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol (2012) 3.51
A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis (2005) 3.46
Population substructure and control selection in genome-wide association studies. PLoS One (2008) 3.44
Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis (2011) 3.44
Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer (2006) 3.38
Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev (2009) 3.33
Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst (2008) 3.32
Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet (2013) 3.25
Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine (2008) 3.17
Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer (2009) 3.15
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol (2006) 3.08
Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst (2003) 3.08
A new statistic and its power to infer membership in a genome-wide association study using genotype frequencies. Nat Genet (2009) 3.06
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis (2013) 3.06
Beyond odds ratios--communicating disease risk based on genetic profiles. Nat Rev Genet (2009) 3.01
The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol (2007) 2.91
Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol (2013) 2.87
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol (2011) 2.85